Pure Global AI
NCT06225947Not yet recruiting

Patient-Reported Outcomes for Lemborexant in Chinese Participants With Insomnia

A Prospective, Multi-center, 3-month, Observational Study to Evaluate the Effectiveness and Safety of Lemborexant in Chinese Patients With Insomnia in Real World Setting.
Guangdong Provincial People's HospitalClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Insomnia
Drug/Device/Intervention
Lemborexant 5 MG
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Guangdong Provincial People's Hospital
Location
Guangzhou,Guangzhou,Guangzhou,Guangzhou,Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Jun 30, 2025
Enrollment
200 participants
Primary outcome

Proportion of patients with insomnia remission

Summary

This study is a prospective, open-label, single arm, multicenter study lasting 12 weeks to
 evaluate effectiveness and safety of lemborexant(LEM). Patient self-evaluation reports and
 safety events will be collected at baseline and 4 visits during treatment.

ICD-10 classifications
Nonorganic insomniaDisorders of initiating and maintaining sleep [insomnias]Sleep disordersSleep disorder, unspecifiedOther sleep disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06225947
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06225947 through Pure Global AI's free database. This phase not specified trial is sponsored by Guangdong Provincial People's Hospital and is currently Not yet recruiting. The study focuses on Insomnia. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.